A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Part of paid clinical trials in Anaheim, California.

Sponsor
Eli Lilly and Company
Study ID
NCT06916065
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much eloralintide and eloralintide with tirzepatide get into the bloodstream and how long it takes the body to eliminate it. There will be 6 cohorts. The study will last up to approximately 26 weeks, excluding screening for Cohorts A and B, 11 weeks for Cohorts C and D, and 12 weeks for Cohorts E and F.

Key Dates

Start date
Apr 9, 2025
Status verified
Jan 2026
Primary completion
Jan 19, 2026
Completion
Jan 19, 2026

Study Design

Enrollment
188 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Eloralintide and Tirzepatide-Cohorts A-D
    Eloralintide and Tirzepatide administered subcutaneously (SC)
  • Experimental: Eloralintide-Cohorts E and F
    Eloralintide administered SC

Primary Outcome Measure

Cohorts A and B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Eloralintide and Tirzepatide [ Time Frame: Day 106 Predose to Approximately Week 26 ]

Locations (3)

FacilityCityStateZIPSite coordinators
Anaheim Clinical Trials, LLCAnaheimCalifornia92801-
Fortrea Clinical Research UnitDaytona BeachFlorida32117-
Fortrea Clinical Research UnitDallasTexas75247-

Find similar trials in Anaheim, CA

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Anaheim Clinical Trials, LLC· Anaheim, CAFortrea Clinical Research Unit· Daytona Beach, FLFortrea Clinical Research Unit· Dallas, TX

Related Studies